Not provided
Not provided
Not provided
Not provided
Not provided
Manufacturing Issues
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Health Service, United Kingdom | OTHER_GOV |
| Zimmer Biomet | INDUSTRY |
| British Heart Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
The REDJUVENATE Trial proposes to test the hypothesis that postoperative organ injury and inflammation will be less if patients undergoing cardiac surgery who are at risk of large volume blood transfusion (defined as the administration of ≥4 units of red cells) receive rejuvenated washed cells compared to standard care (unwashed aged stored cells).
In the REDJUVENATE trial, we propose to establish whether the administration of rejuvenated red cells will reduce inflammation and organ injury in cardiac surgery patients at risk of large volume blood transfusion when compared to standard care. Organ injury and sepsis accounts for the majority of all deaths following cardiac surgery. Once organ injury is established care is primarily supportive and there are no effective treatments. Prevention is therefore a key clinical strategy to prevent death, morbidity and high healthcare costs attributable to these complications. Sepsis and inflammatory organ injury are also the principal causes of death following paediatric cardiac surgery, trauma, non-cardiac complex surgical procedures and in critical care; clinical settings that are also among the principal consumers of blood components. National and international blood management strategies are focused on these patients. Evidence of a clinical benefit attributable to the use of rejuvenated red cells in cardiac surgery patients is therefore likely to translate into more widespread benefits to patients and the National Health Service (NHS).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Cross-matched allogeneic stored red cells will be rejuvenated using rejuvesol® Red Blood Cell Processing Solution (Citra Labs, MA, a Zimmer Biomet Company, IN, USA) with washing and re-suspension in an additive solution prior to transfusion. The rejuvenated red cells will then be administered to the patient as per standard practice and according to established institutional protocols. A maximum of 6 rejuvenated red cell units will be transfused within any 24 hour period. |
|
| Control | Active Comparator | Standard care i.e. Cross-matched allogeneic stored non-rejuvenated, unwashed red cells will be administered to the patient as per standard practice and according to established institutional protocols. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| rejuvesol Solution | Device | The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion. |
| Measure | Description | Time Frame |
|---|---|---|
| Renal injury | measurement of serum creatinine | baseline to 96 hours postoperatively |
| Myocardial injury | measurement of serum troponin | baseline to 72 hours postoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| Protocol compliance measured through protocol deviations | protocol deviations will be aggregated based on pre-defined codes | from date of randomisation through to study completion (3 months) |
| Recruitment |
| Measure | Description | Time Frame |
|---|---|---|
| Acute lung injury | To inform the design of a subsequent efficacy trial | from date of randomisation through to study completion (3 months) |
| Acute kidney injury | To inform the design of a subsequent efficacy trial |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gavin J Murphy, Prof | University of Leicester | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Cardiovascular Sciences | Leicester | Leicestershire | LE3 9QP | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D009102 | Multiple Organ Failure |
| D007249 | Inflammation |
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D012769 | Shock |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Standard Care | Other | Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood & Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols. |
|
measured through recruitment figures
| from date of randomisation through to study completion (3 months) |
| Event rates | measured through serious adverse event (SAE)/ serious unexpected serious adverse reaction (SUSAR) reporting | from date of randomisation through to study completion (3 months) |
| Blinding | measured through protocol deviations | from date of randomisation through to study completion (3 months) |
| Urinary neutrophil gelatinase associated lipocalin (NGAL) | measured through urine collection | baseline to 48 hours postoperatively |
| Serum creatinine | measured to assess renal function | at 6 weeks postoperatively |
| eGFR | measured to assess renal function | at 6 weeks postoperatively |
| Sepsis-related Organ Failure Assessment (SOFA) Score | Sepsis will be defined as suspected or documented infection and an acute change in total SOFA score ≥2 points consequent to the infection. | at baseline, 24, 48, 72 and 96 hours postoperatively |
| Arterial serum lactate | 24 hours postoperatively until time of resolution of hyperlactataemia |
| Lung injury | arterial alveolar oxygen ratios | baseline to 96 hours postoperatively |
| GI tract injury | serum amylase and liver function tests | at baseline, 24, 48, 72, and 96 hours postoperatively |
| Transfusion reactions | measured as part of standard care to assess transfusion safety | from date of randomisation through to study completion (3 months) |
| Age of each unit of red cells transfused | day of operation |
| Postoperative blood loss, transfusion of red cell and non-red cell allogenic blood components | day of operation |
| Adverse events other than those included in the primary endpoint | from date of randomisation through to study completion (3 months) |
| Length of ICU and hospital stay | from date of randomisation through to study completion (3 months) |
| from date of randomisation through to study completion (3 months) |
| Low cardiac output | To inform the design of a subsequent efficacy trial | from date of randomisation through to study completion (3 months) |
| Acute brain injury | To inform the design of a subsequent efficacy trial | from date of randomisation through to study completion (3 months) |
| Acute liver or gut injury | To inform the design of a subsequent efficacy trial | from date of randomisation through to study completion (3 months) |
| Sepsis | To inform the design of a subsequent efficacy trial | from date of randomisation through to study completion (3 months) |
| Organ injury, sepsis or death (a composite of sepsis, acute kidney injury, acute lung injury, acute brain injury, low cardiac output syndrome, gut or liver injury or death) | To inform the design of a subsequent efficacy trial | from date of randomisation through to study completion (3 months) |
| Endothelial function, tissue hypoxia and p50 of circulating red cells | To be measured in a sub-study of mechanisms in 80 participants | baseline and 24 hours post-op |
| Recipient platelet, monocyte and endothelial activation in whole blood as determined using flow cytometry | To be measured in a sub-study of mechanisms in 80 participants | baseline to 48 hours post-op |
| Bronchial aspirate neutrophil and protein concentration | To be measured in a sub-study of mechanisms in 80 participants | 4-6 hours post-op |
| free haem | To be measured in a sub-study of mechanisms in 80 participants | baseline to 96 hours post-op |
| serum bilirubin | To be measured in a sub-study of mechanisms in 80 participants | baseline to 96 hours post-op |
| transferrin saturation | To be measured in a sub-study of mechanisms in 80 participants | baseline to 96 hours post-op |
| non-transferrin bound iron | To be measured in a sub-study of mechanisms in 80 participants | baseline to 96 hours post-op |
| hepcidin | To be measured in a sub-study of mechanisms in 80 participants | baseline to 96 hours post-op |
| pulmonary leucocyte haem oxygenase-1 expression | To be measured in a sub-study of mechanisms in 80 participants | baseline to 96 hours post-op |
| serum protein carbonylation and lipid peroxidation | To be measured in a sub-study of mechanisms in 80 participants | baseline to 96 hours post-op |
| D018746 |
| Systemic Inflammatory Response Syndrome |